24 papers
Pharmacology and therapeutics sits at the exciting intersection where chemical compounds meet human health, focusing on how medicines work within the body and how they can best be used to treat disease. This field explores everything from the initial discovery of new drug molecules to understanding their safety, dosage, and real-world effectiveness in diverse patient populations. It is the science of turning laboratory findings into practical treatments that improve lives.
On Gist.Science, we bridge the gap between rapid scientific discovery and public understanding by curating the latest preprints from medRxiv dedicated to this vital area. Our team processes every new submission in this category, transforming complex research into both accessible plain-language explanations and detailed technical summaries. This ensures that whether you are a researcher or a curious reader, you can grasp the nuances of emerging therapies without getting lost in dense jargon.
Below are the most recent pharmacology and therapeutics papers from medRxiv, ready for you to explore.
This study analyzes Tanzania's 2010–2016 antibiotic import data to reveal that pricing is systematically influenced by formulation type, supplier origin, and naming practices, highlighting the need for import-level monitoring to guide procurement and stewardship policies in low- and middle-income countries.
This study evaluated the performance of biomedical Large Language Models combined with specific prompting strategies and causality algorithms on 150 Individual Case Safety Reports, finding that while the Medicine LLaMA-3 8B model with Chain-of-Thought prompting achieved the highest agreement with human experts (64%), these models remain suboptimal for reliable individual-level causality assessment in pharmacovigilance.
This retrospective, propensity score-matched study using the TriNetX network found that the addition of GLP-1 receptor agonists to lithium therapy in adults with type 2 diabetes was associated with a significantly lower incidence of renal nephrotoxicity compared to lithium therapy alone.
This study characterizes the sociodemographic and clinical profiles of 15,477 All of Us participants prescribed GLP-1 receptor agonists, demonstrating that the program's diverse, multi-modal dataset is a robust resource for future real-world research on these rapidly expanding treatments.